These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37374378)

  • 1. New Options for Systemic Therapies in Intrahepatic Cholangiocarcinoma (iCCA).
    Becht R; Wasilewicz MP
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma.
    Bath NM; Pawlik TM
    Chin Clin Oncol; 2023 Feb; 12(1):5. PubMed ID: 36922354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
    Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
    Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach.
    Merath K; Tiwari A; Parikh AA; Pawlik TM
    Future Oncol; 2023 Dec; 19(39):2607-2621. PubMed ID: 38108100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Aitcheson G; Mahipal A; John BV
    Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
    [No Abstract]   [Full Text] [Related]  

  • 6. Systemic treatment of advanced or recurrent biliary tract cancer.
    Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
    Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic therapies for intrahepatic cholangiocarcinoma.
    Kelley RK; Bridgewater J; Gores GJ; Zhu AX
    J Hepatol; 2020 Feb; 72(2):353-363. PubMed ID: 31954497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
    Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
    Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
    Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
    Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging molecular therapeutic targets for cholangiocarcinoma.
    Ilyas SI; Gores GJ
    J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians.
    Moris D; Palta M; Kim C; Allen PJ; Morse MA; Lidsky ME
    CA Cancer J Clin; 2023 Mar; 73(2):198-222. PubMed ID: 36260350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of ivosidenib for the treatment of
    Tella SH; Mahipal A
    Expert Opin Pharmacother; 2022 Dec; 23(17):1879-1885. PubMed ID: 36257911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma.
    Saborowski A; Vogel A; Segatto O
    Trends Cancer; 2022 Feb; 8(2):83-86. PubMed ID: 34840108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.
    Brown ZJ; Ruff SM; Pawlik TM
    Expert Rev Anticancer Ther; 2023 Mar; 23(3):257-264. PubMed ID: 36744395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR2 Inhibition in Cholangiocarcinoma.
    Vogel A; Segatto O; Stenzinger A; Saborowski A
    Annu Rev Med; 2023 Jan; 74():293-306. PubMed ID: 36170665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How I treat biliary tract cancer.
    Lamarca A; Edeline J; Goyal L
    ESMO Open; 2022 Feb; 7(1):100378. PubMed ID: 35032765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma.
    Tsujie M; Iwai T; Kubo S; Ura T; Hatano E; Sakai D; Takeda Y; Kaibori M; Kobayashi T; Katanuma A; Katayose Y; Fukase K
    Jpn J Clin Oncol; 2021 May; 51(6):911-917. PubMed ID: 33822966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
    Komuta M
    Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma.
    Zhang Z; Wang G; Du L; Zhao J; Pan L; Zhang G; Wang F; Liu R
    Front Immunol; 2023; 14():1124482. PubMed ID: 37292215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications.
    Kankeu Fonkoua LA; Serrano Uson Junior PL; Mody K; Mahipal A; Borad MJ; Roberts LR
    Expert Opin Ther Targets; 2022 Jan; 26(1):79-92. PubMed ID: 35034558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.